The estimated Net Worth of Marianne Zhen is at least $1.68 Million dollars as of 15 November 2023. Ms. Zhen owns over 10,994 units of Innoviva Inc stock worth over $779,065 and over the last 6 years she sold INVA stock worth over $350,156. In addition, she makes $551,918 as Chief Accounting Officer at Innoviva Inc.
Sign up
Ms. Zhen INVA stock SEC Form 4 insiders trading
Marianne has made over 4 trades of the Innoviva Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 10,994 units of INVA stock worth $153,806 on 15 November 2023.
The largest trade she's ever made was selling 10,994 units of Innoviva Inc stock on 15 November 2023 worth over $153,806. On average, Marianne trades about 712 units every 52 days since 2018. As of 15 November 2023 she still owns at least 40,158 units of Innoviva Inc stock.
You can see the complete history of Ms. Zhen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marianne Zhen biography
Marianne Y. Zhen CPA serves as Chief Accounting Officer of the Company. Ms. Zhen joined Innoviva in October 2014 as Corporate Controller. Prior to joining Innoviva, Ms. Zhen served as the Corporate Controller at Steelwedge Software Inc. from 2012 to 2014, Intelmate from 2011 to 2012 and Model N, Inc. from 2007 to 2011. Ms. Zhen earned a Bachelor of Science degree in Business Administration with a concentration in Accounting from San Francisco State University. She is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants.
What is the salary of Marianne Zhen?
As the Chief Accounting Officer of Innoviva Inc, the total compensation of Marianne Zhen at Innoviva Inc is $551,918. There are no executives at Innoviva Inc getting paid more.
How old is Marianne Zhen?
Marianne Zhen is 51, she's been the Chief Accounting Officer of Innoviva Inc since 2018. There are 4 older and 3 younger executives at Innoviva Inc. The oldest executive at Innoviva Inc is Jules Haimovitz, 69, who is the Independent Director.
Insiders trading at Innoviva Inc
Over the last 9 years, insiders at Innoviva Inc have traded over $394,127,811 worth of Innoviva Inc stock and bought 682,000 units worth $8,768,520 . The most active insiders traders include Plc Gsk, Alexander J Sarissa Capital..., and Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of $18,199,955. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth $153,806.
What does Innoviva Inc do?
innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.
What does Innoviva Inc's logo look like?
Complete history of Ms. Zhen stock trades at Innoviva Inc
Innoviva Inc executives and stock owners
Innoviva Inc executives and other stock owners filed with the SEC include:
-
Marianne Zhen,
Chief Accounting Officer -
Marianne Zhen CPA,
Chief Accounting Officer -
Pavel Raifeld C.F.A.,
Chief Exec. Officer -
George Bickerstaff,
Independent Director -
Jules Haimovitz,
Independent Director -
Odysseas Kostas,
Independent Chairman of the Board -
Sarah Schlesinger,
Independent Director -
Mark DiPaolo,
Independent Director -
Pavel Raifeld,
Chief Executive Officer -
Paul Pepe,
Director -
Michael W Aguiar,
President & Chief Exec Officer -
Barbara Gayle Duncan,
Director -
William H Waltrip,
Director -
Theodore L Jr Witek,
Sr. VP & Chief Scientific Off. -
Cathy Friedman,
Director -
James L Tyree,
Director -
Michael E. Faerm,
Sr VP & Chief Business Officer -
George B Abercrombie,
Sr. VP & Chief Comm. Officer -
Patrick G Lepore,
Director -
Eric D Esparbes,
SVP and CFO -
Alexander J Sarissa Capital...,
-
Matthew Ronsheim,
See Remarks -
Geoffrey Hulme,
Interim Principal Exec Officer -
Deborah Birx,
Director -
Plc Gsk,
10% owner -
Derek A Small,
Director -
Sapna Srivastava,
Director -
Margaret Koziel,
Chief Medical Officer -
Stephen Basso,
Chief Financial Officer